Summary
87 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 45% a year over the last 3 years.
- Out of every 100 CHF of revenue, 21 CHF is left as net profit.
- It earns 20 CHF a year on every 100 CHF of invested capital.
- It holds more cash than debt: CHF 175.0M against CHF 83.0M.
What to watch
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 14.9 CHF for 1 CHF of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (CHF)
Diluted EPS (CHF)
- Analyst estimate
Revenue grew by 13% a year over 5 years. Over the last 3 years it grew by 16% a year. Earnings per share grew by 45% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 CHF of revenue goes
- Cost of sales 12 CHF
- Research and development 49 CHF
- Sales and administration 15 CHF
- Taxes and other 2.7 CHF
- Net profit 21 CHF
Net profit, industry median (Biotechnology) -7.1 CHF
Out of every 100 CHF of revenue, 21 CHF is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 1.5 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 0
- Sell 0
No analyst has published a price target.
100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.